Updated cannabinoid guidance emphasizes suitable laboratory methods
Health Canada recommends telling laboratories when samples may contain synthesized cannabinoids or their by-products.
editorial AI summary · WeedWatch editorial briefing
The June 25, 2026 guidance warns that some analytical methods may misidentify or incorrectly quantify cannabinoids when less typical substances are present. Communicating sample composition helps laboratories choose appropriately validated methods.
The guidance also addresses hazards from synthesis inputs and by-products in preventive control plans for edible cannabis and extracts. Its recommended controls for other intoxicating cannabinoids should be read alongside the separate mandatory requirements of the Act and Regulations.
Original source
Health Canada ↗Announcement date verified in the Health Canada industry updates index.
This is a brief summary. Read the source for its full wording and context. Regulatory information can change; this publication does not provide individualized compliance advice.